Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Migraine sufferers may get new preventive option

NCT ID NCT07385755

First seen Feb 04, 2026 · Last updated May 24, 2026 · Updated 9 times

Summary

This study tests whether desvenlafaxine, a medication typically used for depression, can reduce how often and how severe migraines are in people who get them frequently. About 440 adults with episodic migraines will take the drug or a placebo for 12 weeks. The main goal is to see if monthly migraine days decrease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430000, China

Conditions

Explore the condition pages connected to this study.